CompBrief BY VELARION

Companies Revolution Medicines, Inc.

Revolution Medicines (RVMD): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Revolution Medicines, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.
CEO total pay$14,672,390CEO Mark Goldsmith · source
Say-on-pay support96.54%Latest vote · source
CEO vs. named peers82nd pct.Of 17 peer CEOs
CEO pay ratio34:1To the median employee · source

CEO pay, last three years

  • $10,411,247FY2023
  • $10,079,491FY2024
  • $14,672,390FY2025

CEO total pay was $14,672,390 in fiscal 2025, up from $10,079,491 in fiscal 2024.

FY2025: salary $812,500 · bonus $0 · stock awards $3,968,076 · option awards $8,995,114

Executives and directors

Jeffrey Cislini · General CounselMargaret Horn · COOMark Goldsmith · CEOStephen Kelsey · PresidentJack Anders · CFOAlexis Borisy · Lead Independent DirectorBarbara Weber, M.D · Former director (through FY2025)Elizabeth McKee Anderson · Independent DirectorFlavia Borellini, Ph.D · Independent DirectorFrank K. Clyburn, Jr · Independent DirectorLorence Kim, M.D · Independent DirectorSandra J. Horning, M.D · Independent DirectorSushil Patel, Ph.D · Independent DirectorThilo Schroeder, Ph.D · Independent Director

Frequently asked questions

Who was the highest-paid executive at Revolution Medicines, Inc. in fiscal 2025?
As disclosed, Mark Goldsmith (President and Chief Executive Officer) was the highest-paid executive at Revolution Medicines, Inc. in fiscal 2025, with total compensation of $14,672,390.
How does Revolution Medicines, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Mark Goldsmith's total compensation ranked at the 82nd percentile of Revolution Medicines, Inc.'s disclosed peer group.
What is Revolution Medicines, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Revolution Medicines, Inc.'s CEO-to-median employee pay ratio was 34:1.
How did shareholders vote on Revolution Medicines, Inc.'s executive compensation?
As disclosed, 96.54% of shareholders supported Revolution Medicines, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Revolution Medicines, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Revolution Medicines, Inc. reported total board compensation of $1,345,462 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Mark Goldsmith$812,500$0$3,968,076$8,995,114$889,700$0$7,000$14,672,390
President and Chief Executive Officer
Stephen Kelsey625,83301,491,0843,378,112461,20007,0005,963,229
President, Research and Development
Stephen FRCPath625,83301,491,0843,378,112461,20007,0005,963,229
President, Research and Development
Margaret Horn582,66601,165,1642,639,727426,50007,0004,821,057
Chief Operating Officer
Jeffrey Cislini523,7500896,2802,030,559261,00007,0003,718,589
General Counsel and Secretary
Jack Anders523,3330831,0961,882,882343,80007,0003,588,111
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Mark Goldsmith$14,672,390$10,079,491$10,411,247↑ +4,592,899
Stephen Kelsey5,963,229———
Stephen FRCPath5,963,229———
Margaret Horn4,821,0574,884,4044,393,399↓ −63,347
Jeffrey Cislini3,718,5892,743,2172,578,790↑ +975,372
Jack Anders3,588,1113,292,5323,047,529↑ +295,579

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation program is designed to align executive interests with those of stockholders by supporting the achievement of primary business goals and attracting/retaining leadership that drives long-term stockholder value. It links executive compensation with short-term and long-term corporate goals and utilizes a mix of fixed and at-risk pay to foster an ownership culture.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)—
Independent consultantCompensia
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Margaret HornOPTION2025-03-01——100,100—$2,639,727
Margaret HornRSU2025-03-01——28,600—1,165,164
Mark GoldsmithRSU2025-03-01——97,400—3,968,076
Stephen KelseyRSU2025-03-01——36,600—1,491,084
Stephen KelseyOPTION2025-03-01——128,100—3,378,112
Jeffrey CisliniRSU2025-03-01——22,000—896,280
Jack AndersRSU2025-03-01——20,400—831,096
Mark GoldsmithOPTION2025-03-01——341,100—8,995,114
Jeffrey CisliniOPTION2025-03-01——77,000—2,030,559
Jack AndersOPTION2025-03-01——71,400—1,882,882
Stephen FRCPathOPTION2025-03-01——128,100—3,378,112
Stephen FRCPathRSU2025-03-01——36,600—1,491,084

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Margaret Horn$1,165,164$0$2,639,7270.0%
Mark Goldsmith3,968,07608,995,1140.0%
Stephen Kelsey1,491,08403,378,1120.0%
Jeffrey Cislini896,28002,030,5590.0%
Jack Anders831,09601,882,8820.0%
Stephen FRCPath1,491,08403,378,1120.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Jeffrey CisliniRSU530—$42,215
Jack AndersRSU725—57,746
Jeffrey CisliniRSU1,613—128,475
Jeffrey CisliniOption1,85518.56—
Jack AndersRSU1,875—149,344
Stephen KelseyRSU2,425—193,151
Margaret HornRSU2,425—193,151
Jack AndersOption2,53818.56—
Jeffrey CisliniOption5,64421.61—
Mark GoldsmithRSU6,500—517,725
Jack AndersOption6,56321.61—
Jeffrey CisliniRSU6,938—552,612
Jack AndersRSU8,313—662,130
Stephen KelseyOption8,48818.56—
Margaret HornOption8,48818.56—
Jeffrey CisliniRSU11,813—940,905
Stephen KelseyRSU12,500—995,625
Margaret HornRSU12,500—995,625
Jack AndersRSU14,850—1,182,803
Jack AndersRSU16,575—1,320,199
Jeffrey CisliniRSU17,875—1,423,744
Mark GoldsmithOption22,68818.56—
Margaret HornRSU23,063—1,836,968
Margaret HornRSU23,238—1,850,907
Jeffrey CisliniOption24,28226.5—
Stephen KelseyRSU28,913—2,302,920
Jack AndersOption29,09426.5—
Stephen KelseyRSU29,738—2,368,632
Mark GoldsmithRSU32,500—2,588,625
Jeffrey CisliniOption41,34429.8—
Stephen KelseyOption43,75026.5—
Margaret HornOption43,75026.5—
Mark GoldsmithRSU50,625—4,032,281
Jack AndersOption51,97529.8—
Jack AndersOption58,01340.74—
Jeffrey CisliniOption62,56340.74—
Mark GoldsmithRSU79,138—6,303,342
Margaret HornOption80,71929.8—
Margaret HornOption81,33240.74—
Stephen KelseyOption101,19429.8—
Stephen KelseyOption104,08240.74—
Mark GoldsmithOption113,43826.5—
Mark GoldsmithOption176,62529.8—
Mark GoldsmithOption277,14440.74—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Alexis BorisyIndependent · Lead Independent Director · Compensation$89,214$117,762$274,248$0—$481,225
Lorence Kim, M.DIndependent · Audit (Chair)76,319117,762274,24800468,329
Elizabeth McKee AndersonIndependent · Compensation (Chair) · Commercialization69,610117,762274,24800461,620
Flavia Borellini, Ph.DIndependent · Compensation · Research and Development (Chair)69,214117,762274,2480—461,225
Sushil Patel, Ph.DIndependent · Audit · Commercialization63,819117,762274,24800455,829
Sandra J. Horning, M.DIndependent · Research and Development53,819117,762274,24800445,829
Frank K. Clyburn JrIndependent · Compensation · Commercialization (Chair)69,391105,169244,93700419,497
Barbara Weber, M.DIndependent · Departed during FY42,335000042,335
Thilo Schroeder, Ph.DIndependent · Audit000000

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$417,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 18,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$533,721
Equity awards (grant-date value)$811,741
All other compensation$0
Total cost of the board$1,345,462

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Revolution Medicines as a peer

Companies that benchmark against RVMD

14 companies name RVMD as a compensation peer

Each company listed discloses RVMD in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named RVMD in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

ARWR Arrowhead PharmaceuticalsMDGL Madrigal PharmaceuticalsKRYS Krystal BiotechNUVL NuvalentCYTK CytokineticsBPMC Blueprint MedicinesROIV Roivant SciencesAPLS Apellis PharmaceuticalsARVN ArvinasCERE Cerevel TherapeuticsCRSP CRISPR TherapeuticsDNLI Denali TherapeuticsNTLA Intellia TherapeuticsITCI Intra-Cellular TherapeuticsIONS Ionis PharmaceuticalsSWTX SpringWorks TherapeuticsPCVX Vaxcyte

Peer reciprocity

The companies Revolution Medicines, Inc. names as compensation peers that name it back in their own disclosed peer groups.

Nuvalent (NUVL)222CRISPR Therapeutics (CRSP)223Denali Therapeutics (DNLI)224SpringWorks Therapeutics (SWTX)225Vaxcyte (PCVX)226

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Roivant Sciences2025Eric Venker$75,000$2,261,908$0$0$24,400,210
2Madrigal Pharmaceuticals2025Bill Sibold918,53112,297,8504,537,1461,438,81419,206,341
3SpringWorks Therapeutics2024Saqib Islam760,0007,899,7606,689,100798,00016,153,317
4Revolution Medicines, Inc.2025Mark Goldsmith812,5003,968,0768,995,114889,70014,672,390
5Vaxcyte2025Grant Pickering800,0004,300,1598,714,048630,00014,458,937
6Blueprint Medicines2024Kathryn Haviland821,3637,472,4804,315,144854,21713,477,004
7Ionis Pharmaceuticals2025Brett Monia1,051,7768,444,8381,438,105013,350,777
8Cytokinetics2025Robert Blum853,0695,150,0195,095,918772,71511,881,456
9Nuvalent2025James Porter652,1004,392,5635,857,906469,51211,393,602
10Cerevel Therapeutics2022N. Anthony Coles642,735010,085,985496,70611,225,426
11Apellis Pharmaceuticals2024Cedric Francois793,1934,779,8324,787,768010,957,451
12Krystal Biotech2025Krish Krishnan846,1674,104,8254,675,093010,442,485
13Intra-Cellular Therapeutics2023Sharon Mates891,6537,749,9840010,086,413
14Arrowhead Pharmaceuticals2025Christopher Anzalone981,0466,810,29201,236,0009,029,861
15Crispr Therapeutics2025Samarth Kulkarni768,6223,474,9002,768,862659,0937,678,477
16Arvinas2025John Houston706,2362,685,8402,671,051457,0006,534,127
17Intellia Therapeutics2025John Leonard708,0002,443,9201,356,32005,063,899
18Denali Therapeutics2025Ryan Watts718,0001,151,8672,180,00304,751,515

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Revolution Medicines, Inc.146%Option 70 · RSU 30not disclosedCompensia
Apellis Pharmaceuticals90.74%RSU 50 · PSU 50not disclosedPay Governance
Arrowhead Pharmaceuticals125%PRSU 70 · RSU 30not disclosedCompensia
Arvinas108%Options 50 · RSU 50not disclosedAon (Aon's Human Capital Solutions practice, a division of Aon plc)
Blueprint Medicines130%RSU 37 · Options 32 · PSU 31Yes — Relative Total Stockholder Return (rTSR)Aon
Cerevel Therapeutics128.8%Options 100not disclosedPay Governance LLC
Crispr Therapeuticsnot disclosednot disclosednot disclosedAlpine Rewards, LLC
Cytokinetics120%RSU 50 · Options 50not disclosedAon Human Capital Solutions
Denali Therapeutics145%not disclosednot disclosedAlpine Rewards
Intellia Therapeutics115%Option 40 · RSU 40 · PSU 20Yes — TSR relative to the Nasdaq Biotechnology IndexAlpine
Intra-Cellular Therapeuticsnot disclosedRSU 75 · PRSU 25Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology IndexAon Consulting, Inc.
Ionis Pharmaceuticalsnot disclosedPRSU 40 · Option 30 · RSU 30Yes — Relative TSRAon
Krystal Biotech100%not disclosednot disclosedCompensia, Inc.
Madrigal Pharmaceuticalsnot disclosedPSU 33.33 · RSU 33.33 · Option 33.33Yes — Relative TSR vs Nasdaq Biotechnology IndexCompensia, Inc.
Nuvalent120%not disclosedNoAlpine Rewards
Roivant Sciencesnot disclosednot disclosednot disclosedAon
SpringWorks Therapeutics140%not disclosedYes — Relative Total Shareholder Return (TSR)Aon
Vaxcyte105%not disclosednot disclosedPay Governance

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-18155,110,8255,554,146176,73396.54%Passed
20252025-06-26145,265,8252,597,92029,32298.24%Passed
20242024-06-20128,861,4031,624,74827,02998.75%Passed
20232023-06-0888,731,273773,1427,23299.14%Passed
20222022-06-1653,362,3784,631,42014,81592.01%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-06-1896.54%a
20252025-06-2698.24%b
20242024-06-2098.75%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered votes cast for the foregoing purpose, and will have no effect on the vote for this proposal.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered votes cast for the foregoing purpose, and will have no effect on the vote for this proposal.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes are not considered votes cast for the foregoing purpose, and will have no effect on the vote for this proposal.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)34 : 1
CEO total compensation$14,672,390
Median employee compensation$433,964
Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Anthony ManciniSee Remarks2026-04-27D400$134$53,734CommonForm 4 ↗
Anthony ManciniSee Remarks2026-04-27D1,049133139,388CommonForm 4 ↗
Anthony ManciniSee Remarks2026-04-27D1,671132220,007CommonForm 4 ↗
Anthony ManciniSee Remarks2026-04-27A3,12034104,894CommonForm 4 ↗
Anthony ManciniSee Remarks2026-04-27D3,12000Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26D3,12100Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26D42115565,177CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26D2,000154308,122CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26D700153107,312CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26A3,12134104,928CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11A1,0944246,440CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D8,90600Derivative, Class A CommonForm 4 ↗
Dividend-equivalent accruals2026-06-11—1,094——1 insider, 1 accrual row
Margaret HornChief Operating Officer2026-06-11D20015030,034CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D4,600150688,357Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D1,800149267,702Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D700146102,226Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D885145128,457Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D1,315144189,727Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11A8,90641362,830CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D50014773,636Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-15D60,4001609,674,304Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-15D44,85400Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-15D15,54600Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-15A44,854301,336,649CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-15A15,54641633,344CommonForm 4 ↗
Mark GoldsmithDirector2026-06-16D10,0201561,564,310CommonForm 4 ↗
Anthony ManciniSee Remarks2026-06-16D4,615156720,490CommonForm 4 ↗
Stephen KelseySee Remarks2026-06-16D4,175156651,798CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-16D2,722156424,956CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-06-16D2,157156336,749CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17D29,6001604,739,679Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-17D3,30200Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17A25,72527681,713CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17A3,3023098,400CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17A5734123,344CommonForm 4 ↗
Dividend-equivalent accruals2026-06-17—573——1 insider, 1 accrual row
Margaret HornChief Operating Officer2026-06-17D25,72500Derivative, Class A CommonForm 4 ↗
Flavia BorelliniDirector2026-06-18A1,19100CommonForm 4 ↗
Flavia BorelliniDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Frank K. Clyburn JrDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Sandra HorningDirector2026-06-18A1,19100CommonForm 4 ↗
Frank K. Clyburn JrDirector2026-06-18A1,19100CommonForm 4 ↗
Lorence H. KimDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Sushil PatelDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Sandra HorningDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-06-18A1,19100CommonForm 4 ↗
Alexis BorisyDirector2026-06-18A1,19100CommonForm 4 ↗
Lorence H. KimDirector2026-06-18A1,19100CommonForm 4 ↗
Alexis BorisyDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Sushil PatelDirector2026-06-18A1,19100CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24D5,651169956,398CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24D4,553167761,922CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24A20,00019371,200CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24A20,00000Derivative, Class A CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24D30017051,096CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24D9,4961681,597,188CommonForm 4 ↗
Sushil PatelDirector2026-06-29D600191114,327Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D2,95500Derivative, Class A CommonForm 4 ↗
Sushil PatelDirector2026-06-29A2,95538110,931CommonForm 4 ↗
Sushil PatelDirector2026-06-29D30018354,952Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D881193169,693Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D541192103,800Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D10018918,857CommonForm 4 ↗
Sushil PatelDirector2026-06-29D30018856,348Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D858187160,374Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D1,100186204,489Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D900185166,128Common, open-market saleForm 4 ↗
Mark GoldsmithDirector2026-08-21D24521151,809CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D951208198,155CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D3,813210801,670CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D12721226,932CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21A80,0005378,400CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D12621226,720CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D22921148,425CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D12621026,511CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D1,405209294,019CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D937208195,234CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D17720736,684CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D13621028,615CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D1,351209282,739CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D19020739,377CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D3,621212767,933CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D6,5832111,391,206CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D35,9382097,520,440CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D24,9172085,191,948CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D5,1282071,062,691CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D26,60000Derivative, Class A CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D4,500211951,038Common, open-market saleForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D2,540210534,072Common, open-market saleForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D25,8172095,402,200Common, open-market saleForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21A26,60022574,826CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21A29,68019550,861CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D29,68000Derivative, Class A CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D17,3232083,609,573Common, open-market saleForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D3,314212702,761Common, open-market saleForm 4 ↗
Mark GoldsmithDirector2026-08-21D80,00000Derivative, Class A CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D3,400207704,603Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D625206128,846Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D2,128205436,640Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D7,2712041,485,830Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D26,1602045,324,824Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D12,9192022,615,864Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D30020160,168CommonForm 4 ↗
Lorence H. KimDirector2026-08-31D6,5972011,329,117Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D37121278,752Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D4,730211995,678Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D2,853210597,875Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D999207207,125Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D706207145,863Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D3,587209748,081Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D3,844211812,463Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D9,36300Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D6,0192031,223,569Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10A9,36334314,784CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D1,179206242,991Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D30020762,152Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D2,420205496,224Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D5,5302041,128,870Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11A40,031411,630,863CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-11A52,500422,228,625CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-11D52,500422,228,625Derivative, Class A CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-11D3,270206672,991Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D4,9952051,023,189Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D13,3682012,683,986Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D21,4472024,326,947Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D11,8332002,367,955Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D800199158,840Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D17,9492043,659,309Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D18,8692033,831,550Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D40,031411,630,863Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-09-16D7619514,821Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-16D271955,266Common, open-market saleForm 4 ↗
Jack AndersChief Financial Officer2026-09-16D3,992199795,618CommonForm 4 ↗
Jeffrey CisliniSVP & General Counsel2026-09-16D3,314199660,491CommonForm 4 ↗
Jeffrey CisliniSVP & General Counsel2026-09-16D5219510,140Common, open-market saleForm 4 ↗
Mark GoldsmithDirector2026-09-16D21319541,537Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-09-16D4,891199974,792CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-16D5,4841991,092,979CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-16D8519516,576Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-16D1,747199348,183CommonForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-16D33619966,966CommonForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-16D5195975CommonForm 4 ↗
Jack AndersChief Financial Officer2026-09-16D6119511,895CommonForm 4 ↗
Mark GoldsmithDirector2026-09-16D13,7751992,745,402CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-18D1,764197347,402CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D1,500195291,883Common, open-market saleForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D2,648193512,227Common, open-market saleForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D4,985193959,805Common, open-market saleForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D910192174,585Common, open-market saleForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22A5,07015,678CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D5,07000Derivative, Class A CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D10019519,515CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-24D587200117,400CommonForm 4 ↗
Jeffrey CisliniSVP & General Counsel2026-09-25D765207158,600CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-25D3,12100Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-25D3,121201625,885CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-25A3,12134104,928CommonForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D6,00000Derivative, Class A CommonForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D30120561,621Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D1,199204244,485Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D1,000203202,813Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D1,609202324,574Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D2,200201441,801Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29A6,00059353,040CommonForm 4 ↗
Anthony ManciniSee Remarks2026-10-26D2,31000Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-10-26D2,310187431,947CommonForm 4 ↗
Anthony ManciniSee Remarks2026-10-26A2,3103477,662CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 169 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Anthony ManciniSee Remarks2026-04-27D400$134$53,734CommonForm 4 ↗
Anthony ManciniSee Remarks2026-04-27D1,049133139,388CommonForm 4 ↗
Anthony ManciniSee Remarks2026-04-27D1,671132220,007CommonForm 4 ↗
Anthony ManciniSee Remarks2026-04-27A3,12034104,894CommonForm 4 ↗
Anthony ManciniSee Remarks2026-04-27D3,12000Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26D3,12100Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26D42115565,177CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26D2,000154308,122CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26D700153107,312CommonForm 4 ↗
Anthony ManciniSee Remarks2026-05-26A3,12134104,928CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11A1,0944246,440CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D8,90600Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D1,09400Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D20015030,034CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D4,600150688,357Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D1,800149267,702Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D700146102,226Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D885145128,457Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D1,315144189,727Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-11A8,90641362,830CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-11D50014773,636Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-15D60,4001609,674,304Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-15D44,85400Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-15D15,54600Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-15A44,854301,336,649CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-15A15,54641633,344CommonForm 4 ↗
Mark GoldsmithDirector2026-06-16D10,0201561,564,310CommonForm 4 ↗
Anthony ManciniSee Remarks2026-06-16D4,615156720,490CommonForm 4 ↗
Stephen KelseySee Remarks2026-06-16D4,175156651,798CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-16D2,722156424,956CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-06-16D2,157156336,749CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17D29,6001604,739,679Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-06-17D3,30200Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17A25,72527681,713CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17A3,3023098,400CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17A5734123,344CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17D57300Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-06-17D25,72500Derivative, Class A CommonForm 4 ↗
Flavia BorelliniDirector2026-06-18A1,19100CommonForm 4 ↗
Flavia BorelliniDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Frank K. Clyburn JrDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Sandra HorningDirector2026-06-18A1,19100CommonForm 4 ↗
Frank K. Clyburn JrDirector2026-06-18A1,19100CommonForm 4 ↗
Lorence H. KimDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Sushil PatelDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Sandra HorningDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-06-18A1,19100CommonForm 4 ↗
Alexis BorisyDirector2026-06-18A1,19100CommonForm 4 ↗
Lorence H. KimDirector2026-06-18A1,19100CommonForm 4 ↗
Alexis BorisyDirector2026-06-18A3,12700Derivative, Class A CommonForm 4 ↗
Sushil PatelDirector2026-06-18A1,19100CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24D5,651169956,398CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24D4,553167761,922CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24A20,00019371,200CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24A20,00000Derivative, Class A CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24D30017051,096CommonForm 4 ↗
Jack AndersChief Financial Officer2026-06-24D9,4961681,597,188CommonForm 4 ↗
Sushil PatelDirector2026-06-29D600191114,327Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D2,95500Derivative, Class A CommonForm 4 ↗
Sushil PatelDirector2026-06-29A2,95538110,931CommonForm 4 ↗
Sushil PatelDirector2026-06-29D30018354,952Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D881193169,693Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D541192103,800Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D10018918,857CommonForm 4 ↗
Sushil PatelDirector2026-06-29D30018856,348Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D858187160,374Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D1,100186204,489Common, open-market saleForm 4 ↗
Sushil PatelDirector2026-06-29D900185166,128Common, open-market saleForm 4 ↗
Mark GoldsmithDirector2026-08-21D24521151,809CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D951208198,155CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D3,813210801,670CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D12721226,932CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21A80,0005378,400CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D12621226,720CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D22921148,425CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D12621026,511CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D1,405209294,019CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D937208195,234CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D17720736,684CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D13621028,615CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D1,351209282,739CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D19020739,377CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D3,621212767,933CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D6,5832111,391,206CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D35,9382097,520,440CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D24,9172085,191,948CommonForm 4 ↗
Mark GoldsmithDirector2026-08-21D5,1282071,062,691CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D26,60000Derivative, Class A CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D4,500211951,038Common, open-market saleForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D2,540210534,072Common, open-market saleForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D25,8172095,402,200Common, open-market saleForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21A26,60022574,826CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21A29,68019550,861CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D29,68000Derivative, Class A CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D17,3232083,609,573Common, open-market saleForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D3,314212702,761Common, open-market saleForm 4 ↗
Mark GoldsmithDirector2026-08-21D80,00000Derivative, Class A CommonForm 4 ↗
Jeffrey CisliniGeneral Counsel2026-08-21D3,400207704,603Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D625206128,846Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D2,128205436,640Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D7,2712041,485,830Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D26,1602045,324,824Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D12,9192022,615,864Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-08-31D30020160,168CommonForm 4 ↗
Lorence H. KimDirector2026-08-31D6,5972011,329,117Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D37121278,752Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D4,730211995,678Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D2,853210597,875Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D999207207,125Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D706207145,863Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D3,587209748,081Common, open-market saleForm 4 ↗
Lorence H. KimDirector2026-09-08D3,844211812,463Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D9,36300Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D6,0192031,223,569Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10A9,36334314,784CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D1,179206242,991Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D30020762,152Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D2,420205496,224Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-10D5,5302041,128,870Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11A40,031411,630,863CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-11A52,500422,228,625CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-11D52,500422,228,625Derivative, Class A CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-11D3,270206672,991Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D4,9952051,023,189Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D13,3682012,683,986Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D21,4472024,326,947Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D11,8332002,367,955Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D800199158,840Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D17,9492043,659,309Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D18,8692033,831,550Common, open-market saleForm 4 ↗
Stephen KelseySee Remarks2026-09-11D40,031411,630,863Derivative, Class A CommonForm 4 ↗
Margaret HornChief Operating Officer2026-09-16D7619514,821Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-16D271955,266Common, open-market saleForm 4 ↗
Jack AndersChief Financial Officer2026-09-16D3,992199795,618CommonForm 4 ↗
Jeffrey CisliniSVP & General Counsel2026-09-16D3,314199660,491CommonForm 4 ↗
Jeffrey CisliniSVP & General Counsel2026-09-16D5219510,140Common, open-market saleForm 4 ↗
Mark GoldsmithDirector2026-09-16D21319541,537Common, open-market saleForm 4 ↗
Margaret HornChief Operating Officer2026-09-16D4,891199974,792CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-16D5,4841991,092,979CommonForm 4 ↗
Stephen KelseySee Remarks2026-09-16D8519516,576Common, open-market saleForm 4 ↗
Anthony ManciniSee Remarks2026-09-16D1,747199348,183CommonForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-16D33619966,966CommonForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-16D5195975CommonForm 4 ↗
Jack AndersChief Financial Officer2026-09-16D6119511,895CommonForm 4 ↗
Mark GoldsmithDirector2026-09-16D13,7751992,745,402CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-18D1,764197347,402CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D1,500195291,883Common, open-market saleForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D2,648193512,227Common, open-market saleForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D4,985193959,805Common, open-market saleForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D910192174,585Common, open-market saleForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22A5,07015,678CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D5,07000Derivative, Class A CommonForm 4 ↗
Elizabeth McKee AndersonDirector2026-09-22D10019519,515CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-24D587200117,400CommonForm 4 ↗
Jeffrey CisliniSVP & General Counsel2026-09-25D765207158,600CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-25D3,12100Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-25D3,121201625,885CommonForm 4 ↗
Anthony ManciniSee Remarks2026-09-25A3,12134104,928CommonForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D6,00000Derivative, Class A CommonForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D30120561,621Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D1,199204244,485Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D1,000203202,813Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D1,609202324,574Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29D2,200201441,801Common, open-market saleForm 4 ↗
Alan B. SandlerChief Development Officer2026-09-29A6,00059353,040CommonForm 4 ↗
Anthony ManciniSee Remarks2026-10-26D2,31000Derivative, Class A CommonForm 4 ↗
Anthony ManciniSee Remarks2026-10-26D2,310187431,947CommonForm 4 ↗
Anthony ManciniSee Remarks2026-10-26A2,3103477,662CommonForm 4 ↗
Sources (226 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Mark Goldsmith. DEF 14A, filed 2026-04-27. Section “EXECUTIVE COMPENSATION TABLES” · page 41. As printed: 14,672,390. View filing ↗
  • Section 01, Stephen Kelsey. DEF 14A, filed 2026-04-27. Section “2025 Summary Compensation Table”. As printed: 5,963,229. View filing ↗
  • Section 01, Stephen FRCPath. DEF 14A, filed 2026-04-27. Section “EXECUTIVE COMPENSATION TABLES”. As printed: 5,963,229. View filing ↗
  • Section 01, Margaret Horn. DEF 14A, filed 2026-04-27. Section “EXECUTIVE COMPENSATION TABLES”. As printed: 4,821,057. View filing ↗
  • Section 01, Jeffrey Cislini. DEF 14A, filed 2026-04-27. Section “EXECUTIVE COMPENSATION TABLES”. As printed: 3,718,589. View filing ↗
  • Section 01, Jack Anders. DEF 14A, filed 2026-04-27. Section “EXECUTIVE COMPENSATION TABLES”. As printed: 3,588,111. View filing ↗
  • Section 03, Margaret Horn OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Margaret Horn RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Mark Goldsmith RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Stephen Kelsey RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Stephen Kelsey OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Jeffrey Cislini RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Jack Anders RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Mark Goldsmith OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Jeffrey Cislini OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Jack Anders OPTION. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Stephen FRCPath OPTION. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 03, Stephen FRCPath RSU. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
  • Section 07, pay ratio. DEF 14A, filed 2026-04-27. Section “CEO Pay Ratio”. As printed: 34 : 1. View filing ↗
  • Section 08, Alexis Borisy. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 481,225. View filing ↗
  • Section 08, Lorence Kim, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 468,329. View filing ↗
  • Section 08, Elizabeth McKee Anderson. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 461,620. View filing ↗
  • Section 08, Flavia Borellini, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 461,225. View filing ↗
  • Section 08, Sushil Patel, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 455,829. View filing ↗
  • Section 08, Sandra J. Horning, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 445,829. View filing ↗
  • Section 08, Frank K. Clyburn Jr. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 419,497. View filing ↗
  • Section 08, Barbara Weber, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 42,335. View filing ↗
  • Section 08, Thilo Schroeder, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Anthony Mancini 2026-04-27. Form 4, filed 2026-04-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-04-27. Form 4, filed 2026-04-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-04-27. Form 4, filed 2026-04-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-04-27. Form 4, filed 2026-04-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-04-27. Form 4, filed 2026-04-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-05-26. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-06-17. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Flavia Borellini 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Flavia Borellini 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank K. Clyburn Jr 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sandra Horning 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank K. Clyburn Jr 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sandra Horning 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alexis Borisy 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alexis Borisy 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-18. Form 4, filed 2026-06-23. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-06-24. Form 4, filed 2026-06-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sushil Patel 2026-06-29. Form 4, filed 2026-07-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-08-21. Form 4, filed 2026-08-25. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lorence H. Kim 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-10. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-11. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Margaret Horn 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Stephen Kelsey 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jack Anders 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mark Goldsmith 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Elizabeth McKee Anderson 2026-09-22. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-24. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Cislini 2026-09-25. Form 4, filed 2026-09-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-25. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-25. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-09-25. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-29. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-29. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-29. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-29. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-29. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-29. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Alan B. Sandler 2026-09-29. Form 4, filed 2026-10-01. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Anthony Mancini 2026-10-26. Form 4, filed 2026-10-28. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-06-22. Item 5.07 · say-on-pay result. As reported: 96.54% (votes for as printed: 155,110,825). View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-27. Item 5.07 · say-on-pay result. As reported: 98.24% (votes for as printed: 145,265,825). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-24. Item 5.07 · say-on-pay result. As reported: 98.75% (votes for as printed: 128,861,403). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 533,721 + equity 811,741 + all other 0 = 1,345,462, summed across the director compensation table rows.
  • Roivant Sciences, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Roivant Sciences's own proxy. As printed: 24,400,210. View filing ↗
  • Madrigal Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. View filing ↗
  • SpringWorks Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-04. CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. View filing ↗
  • Revolution Medicines, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. View filing ↗
  • Vaxcyte, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vaxcyte's own proxy. As printed: 14,458,937. View filing ↗
  • Blueprint Medicines, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Blueprint Medicines's own proxy. As printed: 13,477,004. View filing ↗
  • Ionis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. View filing ↗
  • Cytokinetics, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. View filing ↗
  • Nuvalent, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Nuvalent's own proxy. As printed: 11,393,602. View filing ↗
  • Cerevel Therapeutics, Section 10b CEO total. DEF 14A, filed 2023-04-28. CEO total compensation as printed in Cerevel Therapeutics's own proxy. As printed: 11,225,426. View filing ↗
  • Apellis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. View filing ↗
  • Krystal Biotech, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Krystal Biotech's own proxy. As printed: 10,442,485. View filing ↗
  • Intra-Cellular Therapeutics, Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapeutics's own proxy. As printed: 10,086,413. View filing ↗
  • Arrowhead Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-01-27. CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. View filing ↗
  • Crispr Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Crispr Therapeutics's own proxy. As printed: 7,678,477. View filing ↗
  • Arvinas, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. View filing ↗
  • Intellia Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Intellia Therapeutics's own proxy. As printed: 5,063,899. View filing ↗
  • Denali Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. View filing ↗
  • Section 10a, Nuvalent reciprocity. DEF 14A. Nuvalent names Revolution Medicines, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, CRISPR Therapeutics reciprocity. DEF 14A. CRISPR Therapeutics names Revolution Medicines, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Denali Therapeutics reciprocity. DEF 14A. Denali Therapeutics names Revolution Medicines, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, SpringWorks Therapeutics reciprocity. DEF 14A. SpringWorks Therapeutics names Revolution Medicines, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Vaxcyte reciprocity. DEF 14A. Vaxcyte names Revolution Medicines, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Get the full report — $500